Lp(a) is a cholesterol-rich lipoprotein resembling LDL, but characterized as a genetically determined risk factor for with a different protein composition, consisting of apo B-100 atherosclerosis and thrombosis. Normally, Lp(a) serum and apo(a). Increased blood concentrations of Lda) are strongly levels are closely related to the apo(a) phenotype. We associated with an increased risk for atherosclerosis (8-10) and studied Lp(a) serum levels and apo(a) phenotypes in 136 arterial and venous thrombosis (1 1). Notably in Young patients, young subjects, aged 0.8-24.7 y, including patients with Lda) appears to be an independent risk factor for myocardial glomerular disease and normal renal function (n = 28), infarction ( 12). The proatherogenic and prothrombotic effects of patients with chronic renal failure (n = 201, patients treated Lp Of all, 21 patients had proteinuria in the nephrotic range. and interference with the fibrinol~tic system (8, 99 13).
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~h~ distribution of Lp(a) levels in normal subjects was
In adult Caucasian populations, Lp(a) blood levels are usually skewed to the left with 97% having levels below 300 mg/ low, i.e. the distribution of normal values is shifted to the left; blood levels above 250-300 mg/L indicate a significant risk for L' A subpopulation with increased Lp(a) levels (13-42%) vascular complications, particularly in patients with elevated could be detected in all groups with renal disease, and LDL cholesterol levels (13) (14) (15) . increased mean serum L P (~) levels were found in patients In individuals, L~~) serum levels are under genetic with ne~hrotic range proteinuria, in patients with chronic control and dependent on the phenotype of the apoprotein renal failure, and in patients on peritoneal dialysis. Serum apo(a). According to Utemann el (16) , seven phenotypes of Lda) levels were not with age, gender, type Of different molecular weight can be differentiated by their relative renal disease, renal function or severity of proteinuria, but mobilities to apo B-100 on electrophoresis; these have been were ~ornelat* with the apo(a) phenotype. For a given designated F (faster than B-100), B (similar to B-loo), S 1, S2, phen?w9 Lda) levels knded t 0 . h higher in patients S3, S4 (all slower than B-loo), and 0 (not detectable). Serum than controls. We ~onclude that increased Lda) serum levels of Lp(a) show an inverse correlation with the size of the levels are frequently found in Young patients with chronic apoprotein phenotype, i.e. small phenotypes (F, B, Sl) are assorenal disease, possibly predisposing them to an increased ciated with high and larger phenotypes (S3, S4) with low serum risk for atherosclerosis and thrombosis. (Pediatr Res 34: levels of Lp(a) (16) . Although Lp(a) levels for a given phenotype 772-776,1993) show considerable overlap, it was concluded that about 40% of the variability in the Lp(a) serum concentrations can be exAbbreviations plained by the apo(a) phenotype (17) . Other researchers have identified a greater number of apo(a) phenotypes, but the same Lp(a), lipoprotein(a) inverse correlation between apo(a) size and Lp(a) serum concen-CFR, glomerular filtration rate tration was found (1 8, 19) . Lp(a) can be detected in umbilical cord blood and serum of newborns (20) (21) (22) , and a gradual rise in serum levels has been observed between the ages of 2 and 13 y (23). Previous studies in adults reported increased Lp(a) levels in patients with proteinChronic renal disease is often accompanied by severe dyslipi- (24) (25) (26) and in patients treated with hemdialysis (27) and demia, a known risk factor for cardiovascular disease. In adults, renal transplantation (28) . H~~~~~~ it remains unclear from cardiovascular disease is indeed by far the leading cause of death these studies whether increases in ~p (~) are confined to individin patients On hemdialysis (1) and after renal transplantation uals with a apo(a) phenotype. Neither Lda) serum levels (2), and an increased risk for atherosclerotic ~0mpli~ati0nS is nor am(,) phenotypes have been studied in pediatric patients assumed by many investigators for patients with unremitting with renal disease. nephrotic syndrome (3, 4) . There are only limited data available We therefore determined Lp(a) serum levels and apo(a) pheconcerning risk factom for atherosclerosis in children and ado-notypes in children, adolescents, and young adults with chronic lescents with renal disease (5-7).
renal disease, including patients with glomerular disease and $ Number of subjects (and % of group total) with Lp(a) serum levels > 300 mg/L. Table I . TG, triglycerides; Chol, cholesterol; VLDL-C, cholesterol in the VLDL fraction: LDL-C, cholesterol in the LDL-fraction; HDL-C, cholesterol in the HDL-fraction. Phenotyping of apo(a) isoforms. Phenotyping was performed as described with six sera running (from left to right) in lanes 1, 3, 4, 5, 7, and 8; standards with known phenotypes were run in lanes 2 and 6. The standards include (bands shown from above to below) S3, S2, S1, and B. The sera were classified (from left to right) as S4S3, S4S2, 0, S4, S4S2, and S4S3. The corresponding Lp(a) serum levels were 100, standard, 100, 0, 160, standard, 330, and 340 mg/L. patients included minimal change disease ( 1 3), IgA nephropathy (2), and endoextracapillary glomerulonephritis (1). Ten patients had proteinuria in the nephrotic range (>I g/m2/d); diagnoses were minimal change disease (6), Wegener's granulomatosis (I), focal segmental glomerulosclerosis (I), membranoproliferative glomerulonephritis ( 1 ), and mesangial glomerulonephritis ( 1) .
Chronic renal failure (n = 20). These patients had decreased renal function (GFR < 70 mL/min/1.73 m2) for 6.9 + 4.3 y.
Histologic diagnoses included autoimmune vasculitis (I), congenital nephrosis ( I), focal-segmental glomerulosclerosis ( I), Henoch-Schoenlein purpura (I), hemolytic-uremic syndrome (4), IgA nephropathy (2), membranoproliferative glomemlonephritis (I), oligomeganephronia (I), obstructive uropathy (3), renal hypoplasia/dysplasia (4), and segmental hypoplasia (I). Eight patients had proteinuria in the nephrotic range (1.0 to 34 g/m2/d).
Peritoneal dialysis (n = 16). All patients were treated with continuous peritoneal dialysis for a total of 1.7 + 1.0 y and were anuric. Hemodialysis (n = 10). All patients were treated with hemodialysis for a total of 3.5 + 5.4y and were anuric.
Renal transplantation (n = 23). The patients in this group had a functioning renal transplant for 0.1 to 12.3 y, mean 3.6 + 3.3 y. Renal function varied between 14 and 167 mL/min/ 1.73 mZ (mean 67 + 41 mL/min/1.73 mZ). Twenty-one patients had mild proteinuria (3 1 to 976 mg/m2/d) and three patients had proteinuria in the nephrotic range (1.7,2.5, and 4.9 g/m2/d). All patients were treated with corticosteroids and azathioprine, and all but three received cyclosporin A. Nephrotic range proteinuria (n = 21). Patients in this group belonged to the glomerular disease group (n = lo), the chronic renal failure group (n = 8), and the renal transplantation group (n = 3) and were separately evaluated because of the presence of proteinuria in the nephrotic range ( 1 .O-34 g/m2/d, mean 7.6 + 9.3 e/m2/d). Normal control subjects (n = 39). These children were seen in Gethods: The study was approved by the Ethical Committee the outpatient department for minor illnesses and had normal of the Medical Faculty of the University of Heidelberg. Informed renal function (GFR > 80 mL/min/ 1.73 m2).
consent was obtained from all subjects participating in the study. Glomerular disease (n = 26). The patients in this group had a Lipoprotein projle. Venous blood was drawn in the morning variety of glomerular diseases for 6.5 k 6.0 y and normal renal from nonfasting subjects. Total triglycerides, total cholesterol, function (GFR > 80 mL/min/1.73 m). Sixteen patients had mild and cholesterol in the VLDL fraction, LDL fraction, and HDL proteinuria (145 f 21 1 mg/m2/d); histologic diagnoses in these fraction were measured by routine enzymatic methods (29) . Apo A-I and apo B were measured by turbidimetric methods (Turbitimer, Behring, Marburg, Germany). Lp(a) serum levels. Lp(a) in serum was measured by enzyme immunoassay (Biopool, Umea, Sweden) and by a one-step ELISA method (Immuno, Heidelberg, Germany), which showed a good correlation ( r = 0.897). Results are reported for the enzyme immunoassay. All samples were measured in duplicates. For the enzyme immunoassay, intraassay variability was 6%; interassay variability was 4% for levels > 10 mg/dL. Apo(a) phenotype. The apo(a) phenotypes were separated by SDS-PAGE using a commercially available 4-1 5% gradient gel (PHAST-System, Pharmacia, Freiburg, Germany). This method was modified for Lp(a) detection according to Molinari et al. Renal function. Renal function was estimated by measuring the creatinine clearance in patients with urine output, as well as by calculation of the GFR according to Schwartz et al. (3 1) in all patients and controls.
Proteinuria. Urinary protein was measured using the Coomassie reagent (Bio-Rad, Munich, Germany).
PHENOTYPE
Statistical evaluation. Statistical significance of differences between variables in the groups was calculated by the KruskallWallis test and the Mann-Whitney test [Lp(a) levels for given phenotypes]. Testing for correlations of variables was performed by calculation of the Spearman rank correlation coefficient. Differences in apo(a) phenotype distribution were compared by the x2 test. 
I

Lipoprotein lipids and Lp(a).
Elevated serum levels of lipoprotein lipids and Lp(a) were found in all groups studied (Tables 1  and 2 ). Significant increases in mean Lp(a) levels were found only in the chronic renal failure, nephrotic range proteinuria, and peritoneal dialysis groups (Table I ). The distribution of Lp(a) levels in normal subjects was skewed to the left with 97% of patients having levels below 300 mg/L (Fig. 1) and only one patient with a level above 300 mg/L (320 mg/L). In contrast, the distribution of Lp(a) values in the patient groups was scattered with a shift to the right, and a subpopulation (up to 42%) with increased Lp(a) levels was found in all groups of patients with chronic renal disease (Table 1, Fig. I ). 
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Correlations. The following variables were tested for correlations with Lp(a) serum levels: age, gender, weight, height, body mass index, C-reactive protein level, serum creatinine level, serum total protein level, GFR, and proteinuria. None of these variables were significantly correlated with Lp(a) levels, regardless of whether the groups were tested individually or all patients were combined.
Apo(a) phenotypes. Phenotyping was successfully performed in 130 subjects (Fig. 2) . A single band phenotype was found in 51 (39.2%) and a double band phenotype in 72 (55.3%); no band (phenotype "0") could be detected in seven sera (5.4%). The distribution of phenotypes found in patients and controls was not significantly different ( x 2 = 8.9, p < 0.7). As has been reported previously in normal subjects (14) (15) (16) (17) , there was a strong correlation of the apo(a) phenotype with the serum level of Lp(a) ( Table 3 ). This was most clearly evident in single-band phenotypes; double-band phenotypes were associated with Lp(a) levels that most likely reflect an additive effect of the two alleles (14, 16) . At a cutoff serum Lp(a) level of 300 mg/L, a significant difference in apo(a) phenotype distribution was calculated (xZ = 69.0; p < 0.0001). Figure 3 shows that phenotypes 0, S3, and S4
were exclusively associated with Lp(a) levels below 300 mg/L. However, for most given phenotypes, patients with chronic renal diseases had higher Lp(a) levels, although this finding was not statistically significant in all cases, possibly because of the limited number of comparable subjects (Table 3) .
Lp(a) serum levels were repeatedly evaluated in 10 patients and showed very little variability. In six patients, Lp(a) levels were measured before and after transplantation. Two patients showed an increase in Lp(a) (from 690 and 140 to 840 and 480 mg/L), and three patients showed a decrease (from 200, 160, and 6 10 to 90,80, and 120 mg/L); one patient had an unmeasurable level before and after transplantation. No change in phenotype was noted before and after transplantation.
DISCUSSION
The present study demonstrates that high Lp(a) serum levels are frequently found in young patients with chronic renal disease. Normal children and adolescents had serum levels of Lp(a) that were similarly distributed but somewhat lower than those reported in adult subjects (8) (9) (10) (11) (12) (13) . Elevated Lp(a) levels were present in 13-42% of patients in all groups studied and were not associated with a particular renal disease or the patient's age, gender, degree of renal function, or the severity of proteinuria. Nonfasting conditions may have affected the serum triglyceride levels in our patients, but an effect on Lp(a) serum levels seems unlikely in view of the recent literature (32) .
Previous studies have raised suspicions that serum Lp(a) levels can be affected by chronic renal diseases and metabolic disturbances. Elevations in Lp(a) serum levels have been documented in adults with proteinuria (24) (25) (26) , adults with end-stage renal failure treated by hemodialysis (27) , renal allograft recipients (28) , and children (33) and adults (34) with diabetes mellitus. In addition, alcohol intake (35) and possibly treatment with corticosteroids (25) may have an effect on serum Lp(a) levels.
From the data of Karradi et al. (24) who found a correlation of Lp(a) serum levels with the amount of urinary protein loss, it could be hypothesized that an increase in hepatic Lp(a) production might be the cause of increased Lp(a) levels in patients with the nephrotic syndrome, analogous to the increased hepatic production of VLDL. We could not demonstrate a similar relationship, whether the patients with proteinuria in each group were analyzed separately or pooled together; moreover, increases in Lp(a) were not confined to patients with proteinuria. The fact that Lp(a) levels are not correlated with lipoprotein lipid levels has been found in other studies (8-1 1) and may be further evidence of an altogether different metabolism of this lipoprotein. Our data also indicate that increases in Lp(a) are not dependent on the degree of glomerular function, inasmuch as no correlation was observed with the GFR.
The impression that renal diseases may have a profound influence on Lp(a) is further underscored by the observation of changes in Lp(a) serum levels (but not phenotypes) before and after renal transplantation. It cannot be ruled out that these changes may have been induced by immunosuppressive drug treatment. Webb et al. (28) have recently demonstrated elevated Lp(a) levels in 29% of adult renal allograft recipients; serum levels were significantly higher in patients taking cyclosporin. In the present study, the effect of treatment with steroids and cyclosporin A could not be separately evaluated because almost all of our patients were treated with both drugs. Apart from immunosuppressive treatment (transplanted patients), our patients were treated with a variety of medications, including antihypertensive drugs, phosphate binders, vitamin D analogues, and erythropoietin. However, we could not detect a relationship between any particular medication and increased Lp(a) levels. It is known that Lp(a) serum levels are not affected by diet and most lipid-lowering drugs.
From the studies of Utermann et a/. ( 16) and others (17) (18) (19) , it is apparent that small apo(a) phenotypes are associated with high Lp(a) levels and larger apo(a) phenotypes with lower levels. Our data indicate that this relationship is also present in patients with chronic renal diseases. However, Lp(a) serum levels for almost all phenotypes were shifted toward higher values; therefore, elevated Lp(a) levels > 300 mg/L with a high atherogenic potential occurred in patients with double-band phenotypes and with the smaller phenotypes F, B, S 1, and S2, but were absent in phenotypes S3 and S4. The physiologic mechanisms of Lp(a) regulation are yet unknown; however, the present study shows that chronic renal diseases may interfere with the normal synthesis and/or catabolism of Lp(a), regardless of the apo(a) phenotype. The kidney might have a role in the catabolism of Lp(a) (36) . Because of its strong affinity to glycosaminoglycans (37), Lp(a) could bind to glomerular basement membranes; by inhibiting fibrinolysis, Lp(a) could thus play a role in the progression of renal disease (26) .
In patients with chronic renal diseases, further prospective studies are needed to evaluate the clinical significance of increased Lp(a) levels. Thus, high Lp(a) levels might help identify those patients with chronic renal disease with an increased risk for atherosclerotic and thrombotic complications. This may be of special importance in young patients with potentially lifelong exposure to this risk factor.
